Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer
DOI: 10.1055/s-0045-1808094
Original Article

Clinical Audit of Denosumab Biosimilar for Aggressive GCT of Bone: A Tertiary Care Center Retrospective Analysis

Rajesh B. Singh
1   Surgical Oncology (Orthopedics Oncology), Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India
,
Saravana K. Jagannathan
1   Surgical Oncology (Orthopedics Oncology), Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India
,
Kumar Vineet 
2   Department of Surgical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objectives

Giant cell tumor of bone (GCTB) is a locally aggressive tumor with a high recurrence rate. Using denosumab or its biosimilar in a neoadjuvant setting can facilitate limb-preserving surgery and reduce recurrence rates, with minimal side effects.

Material and Methods

In this clinical audit, we retrospectively analyzed the impact of denosumab biosimilar (DB) on Campanacci grade 3 GCTB, the most aggressive form of these tumors.

Statistical Analysis

Means and standard deviations were used for normally distributed continuous variables, medians and ranges for nonnormal continuous variables, and percentages for categorical variables.

Results

All cases received two doses of DB on days 0 and 14, resulting in a mean lesion size reduction of 17.75%.

Conclusion

Our findings suggest that this treatment regimen can significantly improve outcomes for patients with aggressive GCTB, aiding orthopaedic oncologists in managing these challenging cases more effectively.

Keywords

GCT - denosumab - biosimilar - tumor - recurrence

Statements and Declarations

The authors declare no competing or financial interests. No funding was received for this study.


Principles of Declaration of Helsinki were followed in this retrospective analysis.


Authors' Contributions

R.B.S. conceived the idea and revised the manuscript. S.K.J. collected the data and wrote the manuscript. K.V. analyzed the data and also contributed to writing the manuscript.




Publication History

Received: 02 October 2024

Accepted: 24 March 2025

Article published online:
23 April 2025

© 2025. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Becker RG, Galia CR, Pestilho JFCS, Antunes BP, Baptista AM, Guedes A. Giant cell tumor of bone: a multicenter epidemiological study in Brazil. Acta Ortop Bras 2024; 32 (01) e273066
    PubMedSearch in Google Scholar
  • 2 Sobti A, Agrawal P, Agarwala S, Agarwal M. Giant cell tumor of bone - an overview. Arch Bone Jt Surg 2016; 4 (01) 2-9
    PubMedSearch in Google Scholar
  • 3 Borkowska AM, Szumera-Ciećkiewicz A, Szostakowski B, Pieńkowski A, Rutkowski PL. Denosumab in giant cell tumor of bone: multidisciplinary medical management based on pathophysiological mechanisms and real-world evidence. Cancers (Basel) 2022; 14 (09) 2290
    PubMedSearch in Google Scholar
  • 4 Cooper AS, Travers B. Surgical Essays. London, England: Cox Longman & Co; 1818: 178-179
    Search in Google Scholar
  • 5 Jaffe HL, Lichtenstein L, Portis RB. Giant cell tumor of bone. Its pathologic appearance, grading, supposed variants and treatment. Arch Pathol (Chic) 1940; 30 (03) 993-1031
    Search in Google Scholar
  • 6 Wu PF, Tang JY, Li KH. RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects. Tumour Biol 2015; 36 (02) 495-501
    PubMedSearch in Google Scholar
  • 7 Mavrogenis AF, Igoumenou VG, Megaloikonomos PD, Panagopoulos GN, Papagelopoulos PJ, Soucacos PN. Giant cell tumor of bone revisited. SICOT J 2017; 3: 54
    PubMedSearch in Google Scholar
  • 8 Tsukamoto S, Mavrogenis AF, Kido A, Errani C. Current concepts in the treatment of giant cell tumors of bone. Cancers (Basel) 2021; 13 (15) 3647
    PubMedSearch in Google Scholar
  • 9 Branstetter DG, Nelson SD, Manivel JC. et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012; 18 (16) 4415-4424
    CrossrefPubMedSearch in Google Scholar
  • 10 Puri A, Agarwal M. Treatment of giant cell tumor of bone: current concepts. Indian J Orthop 2007; 41 (02) 101-108
    CrossrefPubMedSearch in Google Scholar
  • 11 Konishi E, Outani H, Mano M. et al. Giant cell tumor of bone - analysis of 213 cases involving extra-craniofacial bones. Pathol Int 2021; 71 (08) 500-511
    PubMedSearch in Google Scholar
  • 12 Purohit S, Pardiwala DN. Imaging of giant cell tumor of bone. Indian J Orthop 2007; 41 (02) 91-96
    PubMedSearch in Google Scholar
  • 13 Rekhi B, Dave V. Giant cell tumor of bone: an update, including spectrum of pathological features, pathogenesis, molecular profile and the differential diagnoses. Histol Histopathol 2023; 38 (02) 139-153
    PubMedSearch in Google Scholar
  • 14 Beebe-Dimmer JL, Cetin K, Fryzek JP, Schuetze SM, Schwartz K. The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004). Rare Tumors 2009; 1 (02) e52
    PubMedSearch in Google Scholar
  • 15 van Langevelde K, McCarthy CL. Radiological findings of denosumab treatment for giant cell tumours of bone. Skeletal Radiol 2020; 49 (09) 1345-1358
    PubMedSearch in Google Scholar
  • 16 Srikanth E, Kancherla NR, Arvind B. et al. Campanacci grade III giant cell tumors of distal end radius treated with wide excision and reconstruction: a retrospective case series. Cureus 2022; 14 (08) e27818
    PubMedSearch in Google Scholar
  • 17 Xu SF, Adams B, Yu XC, Xu M. Denosumab and giant cell tumour of bone-a review and future management considerations. Curr Oncol 2013; 20 (05) e442-e447
    PubMedSearch in Google Scholar
  • 18 Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 2011; 469 (02) 591-599
    CrossrefPubMedSearch in Google Scholar
  • 19 Hu P, Zhao L, Zhang H. et al. Recurrence rates and risk factors for primary giant cell tumors around the knee: a multicentre retrospective study in China. Sci Rep 2016; 6: 36332
    PubMedSearch in Google Scholar
  • 20 Li H, Gao J, Gao Y, Lin N, Zheng M, Ye Z. Denosumab in giant cell tumor of bone: current status and pitfalls. Front Oncol 2020; 10: 580605
    CrossrefPubMedSearch in Google Scholar